Oliver Luxxe Assets LLC Acquires New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Oliver Luxxe Assets LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 48,318 shares of the biopharmaceutical company’s stock, valued at approximately $4,463,000.

Several other institutional investors also recently modified their holdings of the stock. nVerses Capital LLC acquired a new stake in Gilead Sciences during the 3rd quarter worth approximately $25,000. Valued Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the period. Cedar Wealth Management LLC grew its stake in shares of Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 160 shares during the last quarter. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences in the second quarter valued at $33,000. Finally, Quarry LP acquired a new position in Gilead Sciences during the 2nd quarter worth about $43,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 8,500 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $91.96, for a total value of $781,660.00. Following the sale, the chief financial officer now directly owns 132,373 shares of the company’s stock, valued at approximately $12,173,021.08. This represents a 6.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 453,734 shares of company stock worth $41,902,086 in the last quarter. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Down 0.4 %

Shares of NASDAQ:GILD traded down $0.35 during midday trading on Monday, hitting $91.06. 4,103,792 shares of the company’s stock were exchanged, compared to its average volume of 3,856,787. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a market cap of $113.48 billion, a PE ratio of 1,011.78, a price-to-earnings-growth ratio of 2.24 and a beta of 0.18. The stock has a 50 day moving average price of $91.81 and a 200-day moving average price of $82.68.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same period in the previous year, the company posted $2.29 EPS. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio is 3,422.22%.

Analyst Ratings Changes

GILD has been the subject of several recent research reports. UBS Group increased their price target on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Wolfe Research assumed coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They set an “outperform” rating and a $110.00 target price for the company. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Wells Fargo & Company increased their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, Citigroup assumed coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price on the stock. Twelve investment analysts have rated the stock with a hold rating, twelve have given a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $96.43.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.